MK-677 Research for Growth Hormone Deficiency
An evidence-based overview of research examining MK-677 in the context of growth hormone deficiency. This page synthesizes findings from peer-reviewed literature.
Research Summary
MK-677 increases GH and IGF-1 levels to the range seen in young adults. In elderly subjects, it restored IGF-1 levels that had declined with age. The oral administration route provides a convenient alternative to GH injections. However, the broader hormonal effects (including increased cortisol and potential glucose intolerance) may limit its use as a GH replacement. MK-677 was not approved for GH deficiency. Direct GH replacement remains the standard treatment.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Growth Hormone Deficiency
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. MK-677 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.